News articles about Flex Pharma (NASDAQ:FLKS) have been trending somewhat positive this week, Accern Sentiment Analysis reports. The research group identifies negative and positive press coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Flex Pharma earned a media sentiment score of 0.19 on Accern’s scale. Accern also assigned news headlines about the biotechnology company an impact score of 0 out of 100, indicating that recent press coverage is extremely unlikely to have an effect on the stock’s share price in the immediate future.
FLKS has been the topic of several analyst reports. Zacks Investment Research downgraded shares of Flex Pharma from a “hold” rating to a “sell” rating in a research note on Tuesday, May 23rd. Jefferies Group LLC dropped their target price on shares of Flex Pharma from $9.00 to $8.00 and set a “buy” rating for the company in a research report on Thursday, May 4th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the stock. Flex Pharma currently has a consensus rating of “Buy” and an average price target of $15.40.
Flex Pharma (FLKS) traded down 3.74% during midday trading on Friday, hitting $3.60. 36,868 shares of the stock traded hands. The company has a 50-day moving average of $3.74 and a 200-day moving average of $4.04. The stock’s market cap is $61.30 million. Flex Pharma has a 1-year low of $3.01 and a 1-year high of $12.68.
Flex Pharma (NASDAQ:FLKS) last issued its quarterly earnings results on Wednesday, May 3rd. The biotechnology company reported ($0.49) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.62) by $0.13. Flex Pharma had a negative net margin of 3,043.70% and a negative return on equity of 60.50%. The firm had revenue of $0.24 million during the quarter, compared to the consensus estimate of $0.38 million. On average, equities analysts expect that Flex Pharma will post ($2.41) EPS for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: “Flex Pharma (FLKS) Getting Somewhat Favorable Press Coverage, Accern Reports” was published by BBNS and is the property of of BBNS. If you are reading this piece on another publication, it was copied illegally and republished in violation of U.S. & international trademark and copyright legislation. The legal version of this piece can be viewed at https://baseballnewssource.com/markets/flex-pharma-flks-receiving-somewhat-favorable-press-coverage-accern-reports-updated/1180263.html.
Flex Pharma Company Profile
Flex Pharma, Inc is a biotechnology company. The Company develops treatments for nocturnal leg cramps, muscle cramps and spasms associated with severe neuromuscular conditions, and exercise associated muscle cramps (EAMCs). The Company’s product candidates activate certain receptors in primary sensory neurons, which then act through neuronal circuits to reduce the repetitive firing, or hyperexcitability, of alpha-motor neurons in the spinal cord, thereby preventing or reducing the frequency and intensity of muscle cramps and spasms.
Receive News & Ratings for Flex Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flex Pharma Inc. and related companies with our FREE daily email newsletter.